Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
ORTHO EVRA is an estrogen/progestin combination hormonal contraceptive (CHC), indicated for the prevention of pregnancy in women who elect to use a transdermal patch. (1) Limitation of Use:...
EVRA® 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch PRESCRIBING INFORMATION . ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). Please refer to Summary of Product Characteristics (SmPC) before prescribing. INDICATION(S): Female contraception, intended for women of fertile age. Safety/efficacy
QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE). Each transdermal patch releases an average of 203 micrograms of NGMN and 33.9 micrograms of EE per 24 hours.
The EVRA® (norelgestromin and ethinyl estradiol) transdermal system is indicated for the prevention of pregnancy. The pharmacokinetic profile for the EVRA ® transdermal system is different from that of
Evra is a transdermal patch version of ‘the pill’ (combined oral contraceptive tablet). Using a weekly transdermal patch instead of a daily pill may help the woman to stick to using her contraception appropriately. The active substances in Evra are two hormones, ethinylestradiol (an oestrogen) and norelgestromin (a progestogen).
